Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Neoplastic Processes

ClinicalTrials.gov lists 4,788 trials for Neoplastic Processes or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 175.

MeSH D009385 Neoplasms Neoplasm C04 C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 1,105 Phase 1/2 Phase 1/2 455 Phase 2 Phase 2 1,277 Phase 2/3 Phase 2/3 65 Phase 3 Phase 3 362 Phase 4 Phase 4 72 Not applicable Not applicable 621 Observational Observational 818 Phase 1 Phase 1 1,105 Phase 1/2 Phase 1/2 455 Phase 2 Phase 2 1,277 Phase 2/3 Phase 2/3 65 Phase 3 Phase 3 362 Phase 4 Phase 4 72 Not applicable Not applicable 621 Observational Observational 818

Trials per phase

2 more sections with rows

18 of the 4,788 trials are tagged with Neoplastic Processes itself; the rest are tagged with a narrower condition beneath it.

Get the Neoplastic Processes report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Neoplastic Processes trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 7 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 306

1990: 2 trials (Observational 1, Phase 2 1) 1991: 5 trials (Observational 1, Phase 3 1, Phase 2 1, Phase 1 2) 1992: 6 trials (Phase 3 2, Phase 2 2, Phase 1 2) 1993: 3 trials (Observational 1, Phase 1/2 1, Phase 1 1) 1994: 9 trials (Observational 1, Not applicable 1, Phase 3 2, Phase 2 3, Phase 1 2) 1995: 9 trials (Phase 2 3, Phase 1/2 2, Phase 1 4) 1996: 14 trials (Observational 2, Phase 3 6, Phase 2 4, Phase 1 2) 1997: 27 trials (Observational 2, Not applicable 4, Phase 3 3, Phase 2 5, Phase 1/2 1, Phase 1 12) 1998: 42 trials (Not applicable 1, Phase 4 1, Phase 3 8, Phase 2/3 2, Phase 2 16, Phase 1/2 4, Phase 1 10) 1999: 56 trials (Observational 4, Not applicable 2, Phase 3 9, Phase 2 19, Phase 1/2 4, Phase 1 18) 2000: 54 trials (Observational 1, Not applicable 5, Phase 4 1, Phase 3 8, Phase 2 20, Phase 1/2 4, Phase 1 15) 2001: 64 trials (Observational 2, Not applicable 4, Phase 4 2, Phase 3 9, Phase 2/3 2, Phase 2 19, Phase 1/2 11, Phase 1 15) 2002: 66 trials (Not applicable 4, Phase 4 3, Phase 3 18, Phase 2/3 1, Phase 2 27, Phase 1/2 6, Phase 1 7) 2003: 83 trials (Observational 10, Not applicable 4, Phase 4 3, Phase 3 10, Phase 2/3 1, Phase 2 35, Phase 1/2 7, Phase 1 13) 2004: 110 trials (Observational 10, Not applicable 7, Phase 4 3, Phase 3 13, Phase 2/3 1, Phase 2 41, Phase 1/2 8, Phase 1 27) 2005: 134 trials (Observational 12, Not applicable 8, Phase 4 2, Phase 3 13, Phase 2 56, Phase 1/2 15, Phase 1 28) 2006: 160 trials (Other 2, Observational 18, Not applicable 9, Phase 4 3, Phase 3 19, Phase 2/3 1, Phase 2 65, Phase 1/2 10, Phase 1 33) 2007: 141 trials (Other 1, Observational 19, Not applicable 5, Phase 4 1, Phase 3 10, Phase 2/3 3, Phase 2 69, Phase 1/2 5, Phase 1 28) 2008: 134 trials (Other 1, Observational 20, Not applicable 10, Phase 4 3, Phase 3 15, Phase 2/3 2, Phase 2 35, Phase 1/2 13, Phase 1 35) 2009: 159 trials (Other 1, Observational 24, Not applicable 13, Phase 4 1, Phase 3 13, Phase 2/3 1, Phase 2 56, Phase 1/2 14, Phase 1 36) 2010: 166 trials (Observational 32, Not applicable 25, Phase 4 2, Phase 3 9, Phase 2 46, Phase 1/2 10, Phase 1 42) 2011: 150 trials (Observational 16, Not applicable 14, Phase 4 5, Phase 3 9, Phase 2/3 1, Phase 2 53, Phase 1/2 8, Phase 1 44) 2012: 160 trials (Observational 26, Not applicable 17, Phase 4 3, Phase 3 16, Phase 2/3 5, Phase 2 42, Phase 1/2 11, Phase 1 40) 2013: 172 trials (Observational 30, Not applicable 19, Phase 4 4, Phase 3 8, Phase 2 56, Phase 1/2 15, Phase 1 40) 2014: 190 trials (Observational 35, Not applicable 34, Phase 4 3, Phase 3 10, Phase 2/3 3, Phase 2 53, Phase 1/2 17, Phase 1 35) 2015: 163 trials (Observational 39, Not applicable 29, Phase 4 5, Phase 3 12, Phase 2/3 3, Phase 2 29, Phase 1/2 9, Phase 1 37) 2016: 191 trials (Observational 36, Not applicable 34, Phase 4 2, Phase 3 12, Phase 2/3 5, Phase 2 38, Phase 1/2 12, Phase 1 52) 2017: 177 trials (Observational 29, Not applicable 33, Phase 4 3, Phase 3 8, Phase 2/3 4, Phase 2 44, Phase 1/2 15, Phase 1 41) 2018: 202 trials (Observational 43, Not applicable 33, Phase 4 3, Phase 3 9, Phase 2/3 6, Phase 2 44, Phase 1/2 23, Phase 1 41) 2019: 206 trials (Observational 47, Not applicable 26, Phase 4 3, Phase 3 11, Phase 2/3 4, Phase 2 51, Phase 1/2 22, Phase 1 42) 2020: 216 trials (Observational 44, Not applicable 35, Phase 3 8, Phase 2 46, Phase 1/2 32, Phase 1 51) 2021: 306 trials (Observational 57, Not applicable 56, Phase 4 4, Phase 3 19, Phase 2/3 3, Phase 2 60, Phase 1/2 42, Phase 1 65) 2022: 251 trials (Observational 59, Not applicable 47, Phase 4 2, Phase 3 18, Phase 2 35, Phase 1/2 35, Phase 1 55) 2023: 232 trials (Observational 54, Not applicable 37, Phase 3 13, Phase 2/3 2, Phase 2 36, Phase 1/2 29, Phase 1 61) 2024: 226 trials (Observational 56, Not applicable 34, Phase 4 2, Phase 3 10, Phase 2/3 2, Phase 2 49, Phase 1/2 10, Phase 1 63) 2025: 209 trials (Observational 38, Not applicable 33, Phase 4 3, Phase 3 18, Phase 2/3 7, Phase 2 35, Phase 1/2 18, Phase 1 57)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 245
2025 209
2024 226
2023 232
2022 251
2021 306
2020 216
2019 206
2018 202
2017 177

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 250 trials starting in 2026 and about 230 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 614 trials still running at the 2026-10-09 snapshot; registered median of 37 months across 2,805 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Neoplastic Processes trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 1,105
Phase 1/2 455
Phase 2 1,277
Phase 2/3 65
Phase 3 362
Phase 4 72
Not applicable 621
Observational 818
Expanded access 12
Unknown 1

How many Neoplastic Processes trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 182
Recruiting 710
Enrolling by invitation 13
Active, not recruiting 311
Available 3

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Neoplastic Processes trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 175
Eli Lilly and Company 73
Novartis Pharmaceuticals 54
AstraZeneca 53
Pfizer 41

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Neoplastic Processes? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 152
PEMBROLIZUMAB 142
(nab)-paclitaxel 124
"Capecitabine" 93
NIVOLUMAB 85

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Gemcitabine/Gemzar 120
SQ Fludarabine 115
Bevacizumab 1 98
or carboplatin 93
Fluorouracile 83

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Neoplastic Processes trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 1,795 241
Vomiting 1,099 290
Pyrexia 1,039 201
Febrile neutropenia 950 158
Diarrhoea 879 163

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Neoplastic Processes? (6)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
The role of adiponectin in cancer: a review of current evidence. Endocrine reviews 2012 Yes
Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial. BMC cancer 2024 No
Impact of Microscopic Wall Invasion of the Renal Vein or Inferior Vena Cava on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus: A Multi-institutional Analysis from the International Renal Cell Carcinoma-Venous Thrombus Consortium. European urology focus 2018 No
From pathogenesis to treatment of chronic lymphocytic leukaemia. Nature reviews. Cancer 2010 No
Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer treatment reviews 2004 No

Showing 5 of 6 publications.

Start your 14-day trial Email me all 6 publications as a PDF

Sub-conditions in MeSH (8)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages